Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality
- PMID: 28573191
- PMCID: PMC5441987
- DOI: 10.1097/TXD.0000000000000673
Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality
Abstract
Background: Invasive fungal infections remain a leading cause of morbidity and mortality among liver transplant recipients (LTRs). In this patient population, invasive Candida infections (ICIs) account for the large majority of cases. To date, only small studies and case-series analysing clinical presentation and risk factors for mortality in LTRs with ICIs are available.
Methods: We performed a retrospective multicenter multinational study in 10 centers in Europe and Brazil. All consecutive LTRs developing ICIs during the period January 2011 to December 2013 were included in the study.
Results: A total of 42 LTRs were included. Median age was 52.5 years, and 78.6% of patients were men. Viral hepatitis was the most common cause for liver transplantation (42.9%). Candidemia represented the majority of cases (24, 57.1%), followed by intra-abdominal candidiasis (18, 42.9%). Overall 30-day mortality was 23.8%, with higher mortality in patients with candidemia compared with intra-abdominal candidiasis (37.5% vs 5.6%, P = 0.02). Multivariate analysis showed candidemia to be a risk factor associated with mortality among LTRs presenting ICIs (odds ratio, 11.86; 95% confidence interval, 1.5-280; P = 0.01). Candida albicans represented the most common isolate (59.5%). High rates of antifungal resistances were found, with 16.7% and 4.8% of isolates displaying resistance to azoles and caspofungin, respectively.
Conclusions: Our study confirms the occurrence of high mortality rates in LTRs developing ICIs. Mortality rates varied according to the type of infection, with candidemia representing a risk factor for mortality. The high rates of antifungal resistance should be considered in the choice of the empiric antifungal regimen.
Conflict of interest statement
The authors declare no conflicts of interest.
References
-
- Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50:1101–1111. - PubMed
-
- Yang CH, He XS, Chen J, et al. Fungal infection in patients after liver transplantation in years 2003 to 2012. Ann Transplant. 2012;17:59–63. - PubMed
-
- Rabkin JM, Oroloff SL, Corless CL, et al. Association of fungal infection and increased mortality in liver transplant recipients. Am J Surg. 2000;179:426–430. - PubMed
-
- Liu X, Ling Z, Li L, et al. Invasive fungal infections in liver transplantation. Int J Infect Dis. 2011;15:e298–e304. - PubMed
-
- Winston DJ, Limaye AP, Pelletier S, et al. Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. Am J Transplant. 2014;14:2758–2764. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources